There have been promising results from a trial for low grade ovarian cancer, revealed at the ESMO conference 2019 (European Society for Medical Oncology).

The randomised trial of a drug called trametinib – previously used to treat melanoma – was shown to have an increased response rate compared with standard treatments.


Read the full article